sPLA2 inhibitors
AssigneeEli Lilly and Company
InventorsDouglas Wade Beight, John Michael Morin, Jr., Jason Scott Sawyer, Edward C R Smith
Life of this patent
Estimating the term…
Abstract
A class of novel substituted pyrrole is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
Claims23
A substituted pyrrolo compound represented by the formula (I), or a pharmaceutically acceptable salt, solvate, or prodrug derivative thereof;
- wherein;
- A is S, SO, SO2, O, or NR, and R is a non-interfering substituent;
- R1 is selected from groups (a), (b), and (c) wherein;
- (a) is C7-C20 alkyl, C7-C20 haloalkyl, C7-C20 alkenyl, C7-C20 alkynyl, carbocyclic radical, or heterocyclic radical, or
- (b) is a member of (a) substituted with one or more independently selected non-interfering substituents;
- or
- (c) is the group —(L1)—R11;
- where, —(L1)— is a divalent linking group of 1 to 8 atoms and where R11 is a group selected from (a) or (b);
- R2 is hydrogen, or a group containing 1 to 4 non-hydrogen atom plus any required hydrogen atoms;
- R3 is —(L3)— Z, where —(L3)— is a divalent linker group selected from a bond or a divatent group selected from;
- and Z is selected from a group represented by the formulae,
- wherein, X is oxygen or sulfur;
- and Ra is selected from hydrogen, C1-C8 alkyl, aryl, C1-C8 alkaryl, C1-C8 alkoxy, aralkyl and —CN;
- R4 is the group hydrogen;
- or the group WR4e wherein W is oxygen, Sulfur or NH, and R4e is an alkyl, aryl or an alkylaryl group;
- or the group —(La)—(acidic group);
- wherein —(La)—, is an acid linker having an acid linker length of 1 to 8;
- or the group —(Lh)—(N-hydroxyfunctional amide group);
- wherein —(Lh)—, is an N-hydroxyfunctional amide linker having an N-hydroxyfunctional amide linker length of 1 to 8;
- or the group —(Lc)—(acylamino acid group);
- wherein —(Lc)—, is an acylamino acid linker having an acylamino acid linker length of 1 to 8;
- R5 is selected from hydrogen, a non-interfering substituent, or the group, —(La)—(acidic group);
- wherein —(La)—, is an acid linker having an acid linker length of 1 to 8.
A substituted pyrrole compound represented by the formula (II), or a pharmaceutically acceptable salt, solvate, or prodrug derivative thereof;
- wherein;
- R22 is selected from hydrogen, methyl, ethyl, propyl, isopropyl, cyclopropyl, —F, —CF3, —Cl, —Br, or —O—C3;
- R13 is C2-C8 alkyl;
- and t is an integer from 0 to 5″.
A substituted pyrrole compound represented by the formulae (C1), (C2), (C3), (C4), (C5), (C6), (C7), (C8), (C9), (C10), (C11), (C12), and (C13):
- or a pharmaceutically acceptable salt or prodrug thereof.
Dependencies are inferred from the claim text.